What Do Analysts Predict for EXAS?

By Harris Dyer • Monday, June 12 15:07 • Permanent Link

After this afternoon's 3.8% surge to $91.14 per share, Exact Sciences might just keep moving past its target price of $88.07. With an average analyst rating of buy, and target prices from $73.0 to $100.0, the stock's next move is anyone's guess.

Exact Sciences has an average level of shares sold short, at 5.2% of its total share float. The stock's short ratio (also called days to cover) is 4.37. The company's insiders own 0.92% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 88.2% of Exact Sciences's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Exact Sciences

Date Reported	Holder	Percentage	Shares	Value
2023-03-31	Vanguard Group, Inc. (The)	10%	17,392,288	$1,585,046,204
2023-03-31	JP Morgan Chase & Company	8%	13,950,792	$1,271,405,458
2023-03-31	ARK Investment Management, LLC	6%	11,379,187	$1,037,042,231
2023-03-31	Wellington Management Group, LLP	6%	10,837,455	$987,671,484
2023-03-31	Blackrock Inc.	6%	10,653,553	$970,911,575
2023-03-31	Capital World Investors	4%	6,624,786	$603,749,886
2023-03-31	Baillie Gifford and Company	3%	4,782,346	$435,839,112
2023-03-31	State Street Corporation	3%	4,557,517	$415,349,321
2023-03-31	Ameriprise Financial, Inc.	2%	4,288,325	$390,816,508
2023-03-31	Sumitomo Mitsui Trust Holdings, Inc.	2%	3,778,395	$344,344,036

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.